| 1992 |
Myers ER, Greenspan SL, Hayes WC. Biomechanics of hip fracture risk. In: Proceedings of the 2nd Injury Prevention Through Biomechanics Symposium. April 10-11, 1992; Detroit, MI.41-46. |
0 |
0 |
| 1998 |
Greenspan SL, Myers ER, Kiel DP, Parker RA, Hayes WC, Resnick NM. Fall direction, bone mineral density, and function: risk factors for hip fracture in frail nursing home elderly. Am J Med. June 1998;104(6):539-545. |
33 |
31 |
| 2023 |
Haeri NS, Perera S, Greenspan SL. The association of vitamin d with bone microarchitecture, muscle strength, and mobility performance in older women in long-term care. Bone. November 2023;176:116867. |
0 |
0 |
| 1994 |
Greenspan SL, Myers ER, Maitland LA, Resnick NM, Hayes WC. Fall severity and bone mineral density as risk factors for hip fracture in ambulatory elderly. JAMA. January 12, 1994;271(2):128-133. |
85 |
65 |
| 1994 |
Greenspan SL, Maitland LA, Myers ER, Krasnow MB, Kido TH. Femoral bone loss progresses with age: a longitudinal study in women over age 65. J Bone Miner Res. December 1994;9(12):1959-1965. |
24 |
21 |
| 2008 |
Keaveny TM, Hoffmann PF, Singh M, Palermo L, Bilezikian JP, Greenspan SL, Black DM. Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans. J Bone Miner Res. December 2008;23(12):1974-1982. |
39 |
28 |
| 2016 |
Adler RA, Fuleihan GE-H, Bauer DC, Camacho PM, Clarke BL, Clines GA, Compston JE, Drake MT, Edwards BJ, Favus MJ, Greenspan SL, McKinney R Jr, Pignolo RJ, Sellmeyer DE. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016;31(1):16-35. |
35 |
28 |
| 2020 |
Conley RB, Adib G, Adler RA, Åkesson KE, Alexander IM, Amenta KC, Blank RD, Brox WT, Carmody EE, Chapman‐Novakofski K, Clarke BL, Cody KM, Cooper C, Crandall CJ, Dirschl DR, Eagen TJ, Elderkin AL, Fujita M, Greenspan SL, Halbout P, Hochberg MC, Javaid M, Jeray KJ, Kearns AE, King T, Koinis TF, Koontz JS, Kužma M, Lindsey C, Lorentzon M, Lyritis GP, Michaud LB, Miciano A, Morin SN, Mujahid N, Napoli N, Olenginski TP, Puzas JE, Rizou S, Rosen CJ, Saag K, Thompson E, Tosi LL, Tracer H, Khosla S, Kiel DP. Secondary fracture prevention: consensus clinical recommendations from a multistakeholder coalition. J Bone Miner Res. January 2020;35(1):36-52. |
12 |
9 |
| 2000 |
Bone HG, Greenspan SL, McKeever C, Bell N, Davidson M, Downs RW, Emkey R, Meunier PJ, Miller SS, Mulloy AL, Recker RR, Weiss SR, Heyden N, Musliner T, Suryawanshi S, Yates AJ, Lombardi A; The Alendronate / Estrogen Study Group. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab. February 2000;85(2):720-726. |
10 |
8 |
| 2002 |
Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab. April 2002;87(4):1586-1592. |
23 |
21 |
| 2018 |
Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, Bagur A, Malouf-Sierra J, Lakatos P, Fahrleitner-Pammer A, Lespessailles E, Minisola S, Body JJ, Geusens P, Möricke R, López-Romero P. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. January 20, 2018;391(10117):230-240. |
29 |
24 |
| 2003 |
Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ; PaTH Study Investigators. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. NEJM. September 25, 2003;349(13):1207-1215. |
53 |
47 |
| 2005 |
Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ; PaTH Study Investigators. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. NEJM. August 11, 2005;353(6):555-565. |
34 |
26 |
| 2020 |
Nayak S, Greenspan SL. Cost-effectiveness of five versus ten years of alendronate treatment prior to drug holiday for women with osteoporosis. Osteoporos Int. July 2020;31(7):1273-1282. |
0 |
0 |
| 2020 |
Adami G, Saag KG, Mudano AS, Rahn EJ, Wright NC, Outman RC, Greenspan SL, LaCroix AZ, Nieves JW, Silverman SL, Siris ES, Watts NB, Miller MJ, Ladores S, Curtis JR, Danila MI. Factors associated with the contemplative stage of readiness to initiate osteoporosis treatment. Osteoporos Int. July 2020;31(7):1283-1290. |
0 |
0 |
| 2021 |
Fuggle NR, Singer A, Gill C, Patel A, Medeiros A, Mlotek AS, Pierroz DD, Halbout P, Harvey NC, Reginster J-Y, Cooper C, Greenspan SL. How has COVID-19 affected the treatment of osteoporosis? an IOF-NOF-ESCEO global survey. Osteoporos Int. April 2021;32(4):611-617. |
3 |
2 |
| 2021 |
Singer AJ, Fuggle NR, Gill CB, Patel AR, Medeiros AP, Greenspan SL. COVID-19 and effects on osteoporosis management: the patient perspective from a National Osteoporosis Foundation survey. Osteoporos Int. April 2021;32(4):619-622. |
1 |
1 |
| 2021 |
Fuggle NR, Singer A, Gill C, Patel A, Medeiros A, Mlotek AS, Pierroz DD, Halbout P, Harvey NC, Reginster J-Y, Cooper C, Greenspan SL. Correction to: How has COVID-19 affected the treatment of osteoporosis? an IOF-NOF-ESCEO global survey. Osteoporos Int. April 2021;32(4):801-801. |
1 |
0 |